Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.
A list of letters sent to healthcare professionals in September 2008, to inform of new safety information and advice.
|
Date issued
|
Product
|
Safety information
|
|---|---|---|
|
03/09/2008
|
Tygacil (tigecycline)
 (109Kb)
|
New formulation affects medicines that can be infused simultaneously through Y-site delivery
|
|
05/09/2008
|
Relistor (methylnaltrexone)
(74Kb)
|
Use when response to usual laxative treatment has not been sufficient in adults with advanced illness who have opioid-related constipation. To avoid risk of overdose, patients and carers should be made aware that one vial does not always contain the appropriate single dose
|
|
15/09/2008
|
Fibrotic cardiac valvulopathy
|
See also:
›
Letter from the Chief Medical Officer, Chief Nursing Officer, and Chief Pharmaceutical Officer sent on Sept 16, 2008, about the ORACLE Children Study (external link).
›
ORACLE children study: Outcomes after use of antibiotics in preterm labour
